We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Fox Class B
FOX
$22.2B
| $4.91M | 0.01% |
182,752
-4,468
| -2% | -$119K |
|
|
KALV
627
DELISTED
KalVista Pharmaceuticals
KALV
| $4.84M | 0.01% |
400,000
| – | – |
|
|
EIGR
628
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.8M | 0.01% |
16,667
+10,221
| +159% | +$3.01M |
|
629
Euronet Worldwide
EEFT
$2.93B
| $4.79M | 0.01% |
+50,000
| New | +$4.62M |
|
630
Stoke Therapeutics
STOK
$1.97B
| $4.77M | 0.01% |
200,000
| – | – |
|
631
DXC Technology
DXC
$1.76B
| $4.74M | 0.01% |
287,478
-35,242
| -11% | -$560K |
|
632
Arcturus Therapeutics
ARCT
$177M
| $4.67M | 0.01% |
+100,000
| New | +$3.45M |
|
633
Norwegian Cruise Line
NCLH
$9.22B
| $4.66M | 0.01% |
283,600
+35,600
| +14% | +$522K |
|
634
Invesco
IVZ
$14.1B
| $4.64M | 0.01% |
430,869
-7,100
| -2% | -$63.7K |
|
635
Cincinnati Financial
CINF
$27.5B
| $4.62M | 0.01% |
+72,100
| New | +$4.76M |
|
636
IDEX
IEX
$17.5B
| $4.47M | 0.01% |
28,276
-13,150
| -32% | -$2.01M |
|
637
Ascendis Pharma A/S
ASND
$16B
| $4.44M | 0.01% |
30,000
-10,000
| -25% | -$1.37M |
|
638
Warner Music
WMG
$13.5B
| $4.42M | 0.01% |
+150,000
| New | +$4.68M |
|
639
Steris
STE
$22.7B
| $4.36M | 0.01% |
28,421
-27,064
| -49% | -$4.12M |
|
640
RenaissanceRe
RNR
$13.4B
| $4.28M | 0.01% |
+25,000
| New | +$4.1M |
|
641
Endava
DAVA
$163M
| $4.18M | 0.01% |
86,612
-13,388
| -13% | -$597K |
|
|
CFRX
642
DELISTED
ContraFect Corporation
CFRX
| $4.15M | 0.01% |
8,125
+4,525
| +126% | +$2.22M |
|
|
PARA
643
DELISTED
Paramount Global Class B
PARA
| $4.07M | 0.01% |
+174,408
| New | +$3.36M |
|
644
Aclaris Therapeutics
ACRS
$835M
| $4.05M | 0.01% |
2,500,000
+500,000
| +25% | +$670K |
|
645
PVH
PVH
$4.09B
| $4.01M | 0.01% |
83,500
-1,300
| -2% | -$60.6K |
|
646
Globe Life
GL
$14.3B
| $4M | 0.01% |
53,900
-30,800
| -36% | -$2.34M |
|
647
GeoPark
GPRK
$609M
| $3.92M | 0.01% |
400,000
+271,040
| +210% | +$2.43M |
|
648
Vroom Inc
VRM
$36.7M
| $3.91M | 0.01% |
+938
| New | +$3.64M |
|
|
JNPR
649
DELISTED
Juniper Networks
JNPR
| $3.91M | 0.01% |
170,900
+11,300
| +7% | +$260K |
|
650
Artivion
AORT
$1.31B
| $3.83M | 0.01% |
200,000
-25,000
| -11% | -$530K |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.